Anas Al-Obaidi

Anas Al-Obaidi

Auto-generated profile, based on publicly available information

Anas Al-Obaidi

Department of Bioinformatics and Genetics, Faculty of Engineering and Natural Sciences, Kadir Has University, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Open access
AEAmmar D. Elmezayen
Ammar D. Elmezayen
AAAnas Al-Obaidi
Anas Al-Obaidi
AŞAlp Tegin Şahin
Alp Tegin Şahin
KYKemal Yelekçi
Kemal Yelekçi
In December 2019, COVID-19 epidemic was described in Wuhan, China, and the infection has spread widely affecting hundreds of thousands. Herein, an effort was made to identify commercially available drugs in order to repurpose them against coronavirus by the means of structure-based virtual screening. In addition, ZINC15 library was used to identify novel leads against main proteases. Human TMPRSS2 3D structure was first generated using homology modeling approach. Our molecular docking study showed four potential inhibitors against Mpro enzyme, two available drugs (Talampicillin and Lurasidone) and two novel drug-like compounds (ZINC000000702323 and ZINC000012481889). Moreover, four promising inhibitors were identified against TMPRSS2; Rubitecan and Loprazolam drugs, and compounds ZINC000015988935 and ZINC000103558522. ADMET profile showed that the hits from our study are safe and drug-like compounds. Furthermore, molecular dynamic (MD) simulation and binding free energy calculation using the MM-PBSA method was performed to calculate the interaction energy of the top-ranked drugs.

8 June 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
AAAnas Al-Obaidi
Anas Al-Obaidi
AEAmmar D. Elmezayen
Ammar D. Elmezayen
KYKemal Yelekçi
Kemal Yelekçi
γ-aminobutyric acid aminotransferase (GABA-AT) is a pyridoxal 5′-phosphate (PLP)-dependent enzyme which degrades γ-aminobutyric (GABA) in the brain. GABA is an important inhibitory neurotransmitter that plays important neurological roles in the brain. Therefore, GABA-AT is an important drug target which regulates the GABA level. Novel and potent drug development to inhibit GABA-AT is still very challenging task. In this study, we aimed to devise novel and potent inhibitors against GABA-AT using computer-aided drug design (CADD) tools. However, the human GABA-AT crystal structure is not available yet, and we built the 3D structure of human GABA-AT based on the crystal structure of pig’s liver (Sus Scrofa) enzyme as a template. The generated model was validated with numerous tools such as ProSA and PROCHECK. A set of selected well-known inhibitors have been tested against the modeled GABA-AT. Molecular docking studies have been accomplished via application of Genetic Optimization for Ligand Docking (GOLD), Vina and Autodock 4.2 software to search for potent inhibitors. The best two candidate inhibitors have been computationally examined for absorption, distribution, metabolism, elimination and toxicity descriptors (ADMET) and Lipinski’s rule of 5. Lastly, molecular dynamics (MD) simulations were carried out to inspect the ligands’ binding mode and stability of the active site of human GABA-AT over time. The top ranked ligands exhibited reliable stability throughout the MD simulation. The selected compounds are promising candidates and might be tested experimentally for the inhibition of human GABA-AT enzyme.


7 August 2026 in Network Modeling Analysis in Health Informatics and Bioinformatics
Verified
Journal Article
Closed access
PDF file
AAAnas Al-Obaidi
Anas Al-Obaidi
HHHuszalina Hussin
Huszalina Hussin
NHNur Hasya Abd Halim
Nur Hasya Abd Halim
RZRazauden Mohamed Zulkifli
Razauden Mohamed Zulkifli